Three years ago, the data center industry debated whether liquid cooling would ever be necessary. Two years ago, most ...
Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.
The U.S. commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel cancer immunotherapy for adults with relapsed or ...
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney ...
The Barrington School Committee met Thursday night to discuss the investigation involving a former bus monitor charged with ...
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease ...
The Indonesian government is continuing clinical trials for a dengue vaccine to minimize the spread of the virus. The Food and Drug Monitoring Agency ...
Mono Protocol, Nexchain, and WeWake lead December’s presale market with rising capital flows, strong utility, and active ...
Cryptopolitan on MSN
Could This $0.035 Token Become the Next 30x Altcoin? Phase 6 95% Filled
One new crypto token corresponding to a price of $0.035 is experiencing hype as investors look at finding early trades which ...
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
Investing.com -- Bristol Myers Squibb (NYSE:BMY) stock rose 1.5% Wednesday after the company announced it will continue its ADEPT-2 Phase 3 study for psychosis associated with Alzheimer’s disease ...
Many fliers bristled at being forced to miss important engagements; one alleged that after a nine-hour delay, 'at the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback